Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Chi, Katerina Nicolaou, Vicky Nicolaidou, L. Koumas, A. Mitsidou, C. Pierides, M. Manoloukos, K. Barbouti, F. Melanthiou, C. Prokopiou, G. Vassiliou, P. Costeas (2013)
Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosisLeukemia, 28
J. Nangalia, C. Massie, E. Baxter, Francesca Nice, G. Gundem, D. Wedge, E. Avezov, Juan Li, K. Kollmann, D. Kent, Athar Aziz, A. Godfrey, Jonathon Hinton, I. Martincorena, P. Loo, A. Jones, P. Guglielmelli, P. Tarpey, H. Harding, J. Fitzpatrick, C. Goudie, Christina Ortmann, S. Loughran, K. Raine, David Jones, A. Butler, J. Teague, S. O'meara, Stuart Mclaren, M. Bianchi, Y. Silber, D. Dimitropoulou, D. Bloxham, L. Mudie, M. Maddison, B. Robinson, C. Keohane, C. Maclean, K. Hill, K. Orchard, S. Tauro, Ming-Qing Du, M. Greaves, D. Bowen, B. Huntly, C. Harrison, Nicholas Cross, D. Ron, A. Vannucchi, E. Papaemmanuil, P. Campbell, A. Green (2013)
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.The New England journal of medicine, 369 25
E. Rumi, D. Pietra, V. Ferretti, T. Klampfl, A. Harutyunyan, J. Milosevic, Nicole Them, T. Berg, C. Elena, I. Casetti, C. Milanesi, Emanuela Sant'Antonio, M. Bellini, E. Fugazza, Maria Renna, E. Boveri, C. Astori, C. Pascutto, R. Kralovics, M. Cazzola (2014)
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.Blood, 123 10
G. Rotunno, C. Mannarelli, P. Guglielmelli, A. Pacilli, A. Pancrazzi, L. Pieri, T. Fanelli, A. Bosi, A. Vannucchi (2014)
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.Blood, 123 10
T. Klampfl, H. Gisslinger, A. Harutyunyan, Harini Nivarthi, E. Rumi, J. Milosevic, Nicole Them, T. Berg, B. Gisslinger, D. Pietra, Doris Chen, G. Vladimer, K. Bagienski, C. Milanesi, I. Casetti, Emanuela Sant'Antonio, V. Ferretti, C. Elena, Fiorella Schischlik, Ciara Cleary, M. Six, M. Schalling, Andreas Schönegger, C. Bock, L. Malcovati, C. Pascutto, G. Superti-Furga, M. Cazzola, R. Kralovics (2013)
Somatic mutations of calreticulin in myeloproliferative neoplasms.The New England journal of medicine, 369 25
L. Falchi, S. Verstovsek (2018)
Polycythemia vera and essential thrombocythemiaJournal of Clinical Outcomes Management, 25
G. Barosi, R. Mesa, J. Thiele, F. Cervantes, Peter Campbell, S. Verstovsek, B. Dupriez, Ross Levine, F. Passamonti, J. Gotlib, J. Reilly, A. Vannucchi, C. Hanson, L. Solberg, A. Orazi, A. Tefferi (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatmentLeukemia, 22
M. Wojtaszewska, M. Iwoła, K. Lewandowski (2014)
Frequency and Molecular Characteristics of Calreticulin Gene (CALR) Mutations in Patients with JAK2-Negative Myeloproliferative NeoplasmsActa Haematologica, 133
G. Finazzi, A. Carobbio, P. Guglielmelli, C. Cavalloni, S. Salmoiraghi, A. Vannucchi, M. Cazzola, F. Passamonti, A. Rambaldi, T. Barbui (2014)
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.Blood, 124 16
A. Jones, S. Kreil, K. Zoi, K. Waghorn, Claire Curtis, Lingyan Zhang, J. Score, R. Seear, A. Chase, F. Grand, H. White, C. Zoi, D. Loukopoulos, E. Terpos, Elisavet-Christine Vervessou, B. Schultheis, M. Emig, T. Ernst, E. Lengfelder, R. Hehlmann, A. Hochhaus, D. Oscier, R. Silver, A. Reiter, N. Cross (2005)
Widespread occurrence of the JAK 2 V 617 F mutation in chronic myeloproliferative disorders
H. Andrikovics, Tunde Krahling, K. Balassa, G. Halm, A. Bors, Magdalena Koszarska, Á. Bátai, J. Dolgos, J. Csomor, M. Egyed, A. Sípos, P. Reményi, A. Tordai, T. Masszi (2014)
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutationsHaematologica, 99
A. Tefferi, E. Wassie, T. Lasho, C. Finke, Alem Belachew, R. Ketterling, C. Hanson, A. Pardanani, N. Gangat, A. Wolanskyj (2014)
Calreticulin mutations and long-term survival in essential thrombocythemiaLeukemia, 28
T. Barbui, A. Tefferi, A. Vannucchi, F. Passamonti, R. Silver, R. Hoffman, S. Verstovsek, R. Mesa, J. Kiladjian, R. Hehlmann, A. Reiter, F. Cervantes, C. Harrison, M. Mullin, H. Hasselbalch, S. Koschmieder, M. Marchetti, A. Bacigalupo, G. Finazzi, N. Kroeger, M. Griesshammer, G. Birgegard, G. Barosi (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNetLeukemia, 32
T. Barbui (2015)
CME Information: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management
D. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. Borowitz, M. Beau, C. Bloomfield, M. Cazzola, J. Vardiman (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood, 127 20
J. Vardiman, J. Thiele, D. Arber, R. Brunning, M. Borowitz, A. Porwit, N. Harris, M. Beau, E. Hellström-Lindberg, A. Tefferi, C. Bloomfield (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.Blood, 114 5
A. Trifa, R. Popp, A. Cucuianu, C. Bănescu, Mihaela Tevet, B. Martin, Meilin Murat, Ș. Vesa, D. Dima, Marcela Cândea, M. Militaru, I. Pop (2015)
CALR versus JAK2 mutated essential thrombocythaemia – a report on 141 patientsBritish Journal of Haematology, 168
A. Mital, W. Prejzner, M. Bieniaszewska, A. Hellmann (2015)
Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients.Polskie Archiwum Medycyny Wewnetrznej, 125 12
F. Passamonti, D. Caramazza, B. Mora, R. Casalone, M. Maffioli (2014)
It is time to change thrombosis risk assessment for PV and ET?Best practice & research. Clinical haematology, 27 2
C. Harrison, P. Campbell, G. Buck, K. Wheatley, C. East, D. Bareford, B. Wilkins, J. Walt, J. Reilly, A. Grigg, P. Revell, B. Woodcock, A. Green (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.The New England journal of medicine, 353 1
D. Pietra, Angela Brisci, E. Rumi, Sabrina Boggi, C. Elena, A. Pietrelli, R. Bordoni, M. Ferrari, F. Passamonti, G. Bellis, L. Cremonesi, M. Cazzola (2011)
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasmsHaematologica, 96
H. Gisslinger, M. Gotic, J. Hołowiecki, M. Penka, J. Thiele, H. Kvasnicka, R. Kralovics, P. Petrides (2013)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.Blood, 121 10
AbstractThe impact of the mutation status on the clinical course and the outcome of essential thrombocythemia (ET) patients has not yet been completely established. A total of 171 patients with diagnosed ET were tested and subsequently grouped, according to their mutation status – Janus Kinase 2 (JAK2) – 112 patients, calreticulin (CALR) – 36 patients, and thrombopoietin receptor (MPL) – 5 patients. Moreover, 18 individuals were triple-negative (with non-mutated JAK2, CALR, and MPL). CALR-mutated patients preferentially were male, with higher platelets (PLT) counts (mean PLT = 1 002.3) and lower hemoglobin and hematocrit levels at the diagnosis, compared to the JAK2 (mean PLT = 933.6), MPL (mean PLT = 940.8) and triple-negative patients (mean PLT = 822.6) (p = 0.0035). The patients with CALR mutated, and the triple-negative ones had a lower risk of arterial and venous thrombosis (3% and 5.6% cases at the time of diagnosis, respectively) than the patients with JAK2 mutation (7.2%) (p = 0.9210). The overall survival rate did not differ statistically between the groups.
Acta Haematologica Polonica – de Gruyter
Published: Dec 1, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.